ArticleUnited European gastroenterology journal2022

Budesonide orodispersible tablets for induction of remission in patients with active eosinophilic oesophagitis: A 6-week open-label trial of the EOS-2 Programme.

Stephan Miehlke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.